Latest news with #TIV
The Star
2 days ago
- Automotive
- The Star
Auto industry poised for subdued growth
PETALING JAYA: The automotive sector appears set for a more subdued 2025, with total industry volume (TIV) projected to normalise after last year's record high. Analysts expected a mixed outlook, shaped by softening consumer sentiment, rising competition, and policy uncertainty, but supported in part by new model launches and ongoing infrastructure development. BIMB Research revised its 2025 TIV forecast downwards to 790,000 units, a 2.5% cut from its earlier estimate of 810,000 units. It noted that the adjustment was prompted by weaker-than-expected momentum in the first quarter of 2025 (1Q25), attributed to soft consumer sentiment and lingering uncertainty over the timing of RON95 subsidy rationalisation. However, BIMB Research pointed to a potential sequential recovery in the second half of the year, underpinned by promotional activities, longer working days, and stable loan approval rates. Hong Leong Investment Bank Research (HLIB Research) projected a sharper decline, expecting TIV to fall to 750,000 units in 2025, down 8.2% year-on-year, compared to the Malaysian Automotive Association's (MAA) forecast of 780,000 units. HLIB Research remarked that current order backlogs have further dwindled in 2Q25 and this is expected to continue softening in subsequent quarters as consumer sentiment weakens in tandem with a slower economic outlook as well as petrol subsidy rationalisation in the second half of 2025 (2H25). The sector's performance in 1H25 reflected these trends. According to MAA, TIV in May 2025 rose 12.4% month-on-month to 68,000 units, driven by normalised working days after the April festive holidays. However, on a year-on-year basis, sales fell 3.2%, contributing to a 5% decline in year-to-date volume to 316,700 units. This was largely attributed to easing consumer sentiment following the record 816,700 units achieved in 2024. BIMB Research said it saw structural support for the sector from 'new model launches, rising electric vehicle (EV) popularity, and infrastructure buildout'. Key launches expected in the second half included Perodua's eMO battery electric vehicle, Proton's facelifted X50 and new Saga, and Honda's refreshed Civic. Chinese brands were also stepping up, with Chery's iCAUR electric sports utility vehicles set for an Asean debut in the third quarter and TQ Wuling planning a mass-market electric vehicle (EV) below RM100,000 by year-end. BIMB Research noted: 'This strong pipeline across ICE and EV segments is expected to drive demand and refresh the competitive landscape.' Both BIMB Research and HLIB Research maintained a 'neutral' stance on the sector. BIMB Research cautioned that the sector's recovery is expected to be uneven due to elevated borrowing costs, fragile supply chains, and pricing pressure from Chinese manufacturers. Similarly, HLIB Research said earnings were likely to fall in 2025 on the back of lower sales volume and higher operating costs (aggressive sales campaigns), but partially cushioned by the strengthening of the ringgit. On the EV front, BIMB Research highlighted that 'EV adoption will continue to expand structurally, particularly as the current completely built units import tax exemption is set to expire at the end of 2025'. It forecasts EV market share could reach up to 4% by year-end, driven by broader model offerings and stronger national brand participation. Still, achieving the government's 10,000 public charger target by end-2025 remained challenging, with monthly installations needing to average 730 units. The looming revision of the open market value-based excise duty for completely knocked down vehicles in January 2026 could spur frontloaded purchases in late 2025. BIMB Research noted that any delay or adjustment in the policy could 'further sustain demand momentum in 2H25'.
New Straits Times
25-06-2025
- Automotive
- New Straits Times
Malaysia's auto sales to normalise in 2025 after record year
KUALA LUMPUR: Malaysia's total industry volume (TIV) is expected to normalise down to around 750,000 units, following a record high of 816,700 units in 2024. Hong Leong Investment Bank (HLIB) said the moderation is largely driven by a reduction in order backlogs and a slowdown in new order intake expected in the coming months. Its forecast is lower than Malaysia Automotive Association's forecast, which estimates the TIV at 780,000 units. TIV reached 68,000 units in May 2025, marking a 12.4 per cent increase month-on-month but a 3.2 per cent decline year-on-year, rebounding from a weaker April performance impacted by the Raya holidays. Despite aggressive sales efforts by various original equipment manufacturers (OEMs), year-to-date TIV still declined by 5.0 per cent to 316,700 units, reflecting a market normalisation trend driven by a reduction in order backlogs. "Nevertheless, there is still upside potential from exciting new model launches in 2025, with more aggressive marketing activities to sustain sales by the various OEMs, but at the expense of margins," it said. HLIB said current order backlogs have further dwindled in the second quarter of 2025 (2Q25), and this downward trend is expected to persist in the following quarters. The weakening is attributed to softer consumer sentiment, influenced by a slower economic outlook and the upcoming implementation of petrol subsidy rationalisation in the second half of 2025 (2H25). "We expect earnings for the sector to drop in 2025 due to lower sales volume and higher operating costs (aggressive sales campaigns), but partially cushioned by ringgit strengthening," it added.
Malay Mail
21-05-2025
- Automotive
- Malay Mail
Malaysia's auto sales seen cooling in 2025 after record 2024, says HLIB
KUALA LUMPUR, May 21 — Hong Leong Investment Bank (HLIB) expects the automotive sector's total industry volume (TIV) for 2025 to normalise down to the 750,000-unit level, after achieving a record high of 816,700 units in 2024. The investment bank made the projection primarily due to declining order backlogs and easing new order intakes over the coming months. 'Nevertheless, there is still upside potential from exciting new model launches in 2025, along with more aggressive marketing activities to sustain sales by the various original equipment manufacturers, but at the expense of margins,' it said in a note today. The Malaysian Automotive Association (MAA) projected the 2025 TIV to be at 780,000 units. On Monday, the association reported an expected weak April 2025 sales of 60,527 units, a drop of 16.8 per cent month-on-month (m-o-m), mainly due to fewer active working days during the month of Raya holidays. This brings the year-to-date tally to 248,730 units, down 5.4 per cent year-on-year. Meanwhile, MIDF Amanah Investment Bank Bhd has maintained its 2025 TIV forecast of 792,000, which is broadly in line with MAA's projection of 780,000 units, as high base effects begin to set in. 'With the revised excise duty for completely knocked down vehicles now scheduled to take effect in January 2026, potentially raising car prices by 10 per cent to 30 per cent if the ruling is upheld, there may be some degree of frontloading in demand this year,' it said. It expects TIV in May 2025 to improve m-o-m, supported by stronger demand from East Malaysia ahead of the Kaamatan and Gawai celebrations, as well as a greater number of working days. This would be further supported by sustained interest in new models introduced earlier this year, it added. — Bernama
Yahoo
16-05-2025
- Health
- Yahoo
Saudi Arabia Influenza Vaccine Market Trends, Competition, Forecast and Opportunities, 2020-2024 & 2025-2030 Featuring GSK, Abbott, AstraZeneca, Merck, and Johnson & Johnson
Saudi Arabia's influenza vaccine market, valued at USD 44.26 million in 2024, is projected to grow to USD 53.81 million by 2030, at a CAGR of 3.51%. Key drivers include government health campaigns and increasing public demand. Challenges include vaccine hesitancy and cold chain logistics. Major players are GlaxoSmithKline, AstraZeneca, and Merck. Saudi Arabian Influenza Vaccine Market Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Influenza Vaccine Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Influenza Vaccine Market, valued at USD 44.26 million in 2024, is projected to reach USD 53.81 million by 2030, growing at a CAGR of 3.51%. The nation relies primarily on a trivalent influenza vaccine (TIV), containing inactivated antigens from two subtypes of influenza virus type A and one subtype of type B, to drive its immunization efforts. The Saudi government, particularly through the Ministry of Health (MOH), plays an instrumental role in promoting influenza vaccination initiatives, focusing on high-risk groups such as the elderly, pregnant women, and those with chronic diseases. Efforts through free vaccines at healthcare facilities and mobile units have been pivotal in reducing the seasonal flu burden. Public health awareness has surged since the COVID-19 pandemic, with more individuals prioritizing preventive healthcare, including influenza vaccinations. Nevertheless, vaccine hesitancy caused by misinformation about vaccine safety and efficacy continues to challenge widespread immunization. Key Market Drivers Saudi Arabia's response to the growing prevalence of influenza includes prioritizing vaccination to curb the virus's spread. The nation ranks 82nd worldwide for seasonal influenza mortality, with 30.9 deaths per 100,000 individuals. Studies on Hajj pilgrims show influenza prevalence, prompting healthcare initiatives focusing on immunization. Efforts are further supported by institutions like the King Khaled Eye Specialist Hospital in Riyadh, which provides free vaccines to staff and dependents, ensuring records are electronically maintained for better management. Increasing vaccine access and awareness are propelling the vaccine demand, especially with heightened healthcare consciousness post-pandemic. Surge in Technological Advancements Technological advancements have enhanced vaccine development and production, boosting the influenza vaccine market. Innovations like cell-based and recombinant DNA technologies have improved vaccine effectiveness and production speed. New adjuvants also improve efficacy, particularly for older adults and immunocompromised individuals. Key Market Challenges Maintaining the optimal storage temperature for influenza vaccines remains critical. The hot climate of Saudi Arabia increases cold chain logistics challenges. Disruptions can degrade vaccine effectiveness, necessitating efficient refrigeration methods, particularly in rural areas. Additionally, the limited shelf life of vaccines demands careful inventory management. Key Market Trends The rise in demand for pediatric vaccines aligns with the MOH's initiatives to protect children from influenza, bolstered by services like Careem's home vaccination program. Such efforts reflect the Kingdom's broader public health goals, further impacting influenza vaccine demand and growth. Segmental Insights Inactivated influenza vaccines lead market growth due to their broad suitability and safety for diverse populations. Hospitals have become key vaccination centers, offering convenient access to immunizations and playing a significant role in the market's expansion. Regional Insights Northern & Central Saudi Arabia, including Riyadh, dominate the market, facilitated by healthcare services linked to religious pilgrimages and strong private sector engagement. Key Market Players GlaxoSmithKline plc. Abbott S.A. AstraZeneca PLC Merck Limited Johnson and Johnson Medical Saudi Arabia Limited Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $44.26 Million Forecasted Market Value (USD) by 2030 $53.81 Million Compound Annual Growth Rate 3.5% Regions Covered Saudi Arabia Key Topics Covered: 1. Product Overview1.1. Market Definition1.2. Scope of the Market 2. Research Methodology2.1. Objective of the Study2.2. Baseline Methodology 3. Executive Summary3.1. Overview of the Market 4. Saudi Arabia Influenza Vaccine Market Outlook4.1. Market Size & Forecast4.2. Market Share & Forecast 5. Eastern Influenza Vaccine Market Outlook5.1. Market Size & Forecast5.2. Market Share & Forecast 6. Western Influenza Vaccine Market Outlook6.1. Market Size & Forecast6.2. Market Share & Forecast 7. Northern & Central Influenza Vaccine Market Outlook7.1. Market Size & Forecast7.2. Market Share & Forecast 8. Southern Influenza Vaccine Market Outlook8.1. Market Size & Forecast8.2. Market Share & Forecast 9. Market Dynamics9.1. Drivers9.2. Challenges 10. Market Trends & Developments10.1. Recent Developments 11. Policy & Regulatory Landscape 12. Saudi Arabia Economic Profile 13. Competitive Landscape For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Influenza Vaccine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
16-05-2025
- Health
- Yahoo
Saudi Arabia Influenza Vaccine Market Trends, Competition, Forecast and Opportunities, 2020-2024 & 2025-2030 Featuring GSK, Abbott, AstraZeneca, Merck, and Johnson & Johnson
Saudi Arabia's influenza vaccine market, valued at USD 44.26 million in 2024, is projected to grow to USD 53.81 million by 2030, at a CAGR of 3.51%. Key drivers include government health campaigns and increasing public demand. Challenges include vaccine hesitancy and cold chain logistics. Major players are GlaxoSmithKline, AstraZeneca, and Merck. Saudi Arabian Influenza Vaccine Market Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Influenza Vaccine Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Influenza Vaccine Market, valued at USD 44.26 million in 2024, is projected to reach USD 53.81 million by 2030, growing at a CAGR of 3.51%. The nation relies primarily on a trivalent influenza vaccine (TIV), containing inactivated antigens from two subtypes of influenza virus type A and one subtype of type B, to drive its immunization efforts. The Saudi government, particularly through the Ministry of Health (MOH), plays an instrumental role in promoting influenza vaccination initiatives, focusing on high-risk groups such as the elderly, pregnant women, and those with chronic diseases. Efforts through free vaccines at healthcare facilities and mobile units have been pivotal in reducing the seasonal flu burden. Public health awareness has surged since the COVID-19 pandemic, with more individuals prioritizing preventive healthcare, including influenza vaccinations. Nevertheless, vaccine hesitancy caused by misinformation about vaccine safety and efficacy continues to challenge widespread immunization. Key Market Drivers Saudi Arabia's response to the growing prevalence of influenza includes prioritizing vaccination to curb the virus's spread. The nation ranks 82nd worldwide for seasonal influenza mortality, with 30.9 deaths per 100,000 individuals. Studies on Hajj pilgrims show influenza prevalence, prompting healthcare initiatives focusing on immunization. Efforts are further supported by institutions like the King Khaled Eye Specialist Hospital in Riyadh, which provides free vaccines to staff and dependents, ensuring records are electronically maintained for better management. Increasing vaccine access and awareness are propelling the vaccine demand, especially with heightened healthcare consciousness post-pandemic. Surge in Technological Advancements Technological advancements have enhanced vaccine development and production, boosting the influenza vaccine market. Innovations like cell-based and recombinant DNA technologies have improved vaccine effectiveness and production speed. New adjuvants also improve efficacy, particularly for older adults and immunocompromised individuals. Key Market Challenges Maintaining the optimal storage temperature for influenza vaccines remains critical. The hot climate of Saudi Arabia increases cold chain logistics challenges. Disruptions can degrade vaccine effectiveness, necessitating efficient refrigeration methods, particularly in rural areas. Additionally, the limited shelf life of vaccines demands careful inventory management. Key Market Trends The rise in demand for pediatric vaccines aligns with the MOH's initiatives to protect children from influenza, bolstered by services like Careem's home vaccination program. Such efforts reflect the Kingdom's broader public health goals, further impacting influenza vaccine demand and growth. Segmental Insights Inactivated influenza vaccines lead market growth due to their broad suitability and safety for diverse populations. Hospitals have become key vaccination centers, offering convenient access to immunizations and playing a significant role in the market's expansion. Regional Insights Northern & Central Saudi Arabia, including Riyadh, dominate the market, facilitated by healthcare services linked to religious pilgrimages and strong private sector engagement. Key Market Players GlaxoSmithKline plc. Abbott S.A. AstraZeneca PLC Merck Limited Johnson and Johnson Medical Saudi Arabia Limited Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $44.26 Million Forecasted Market Value (USD) by 2030 $53.81 Million Compound Annual Growth Rate 3.5% Regions Covered Saudi Arabia Key Topics Covered: 1. Product Overview1.1. Market Definition1.2. Scope of the Market 2. Research Methodology2.1. Objective of the Study2.2. Baseline Methodology 3. Executive Summary3.1. Overview of the Market 4. Saudi Arabia Influenza Vaccine Market Outlook4.1. Market Size & Forecast4.2. Market Share & Forecast 5. Eastern Influenza Vaccine Market Outlook5.1. Market Size & Forecast5.2. Market Share & Forecast 6. Western Influenza Vaccine Market Outlook6.1. Market Size & Forecast6.2. Market Share & Forecast 7. Northern & Central Influenza Vaccine Market Outlook7.1. Market Size & Forecast7.2. Market Share & Forecast 8. Southern Influenza Vaccine Market Outlook8.1. Market Size & Forecast8.2. Market Share & Forecast 9. Market Dynamics9.1. Drivers9.2. Challenges 10. Market Trends & Developments10.1. Recent Developments 11. Policy & Regulatory Landscape 12. Saudi Arabia Economic Profile 13. Competitive Landscape For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Influenza Vaccine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
